A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children with Idiopathic Short Stature
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Vosoritide (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 12 May 2025 According to a BioMarin Pharmaceutical media release, the data from this study were presented as a poster presentation at the 2025 Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, Denmark.
- 03 Dec 2024 Status changed from not yet recruiting to recruiting.
- 26 Apr 2024 New trial record